scholarly journals Corrigendum to: The influence of the SARS-CoV-2 pandemic on esophagogastric cancer services: an international survey of esophagogastric surgeons

2021 ◽  
Author(s):  
Sivesh K Kamarajah ◽  
Sheraz R Markar ◽  
Pritam Singh ◽  
Ewen A Griffiths ◽  
Keyword(s):  
International Survey ◽  
Cancer Services ◽  
Esophagogastric Cancer

scholarly journals The influence of the SARS-CoV-2 pandemic on esophagogastric cancer services: an international survey of esophagogastric surgeons

2020 ◽  
Vol 33 (7) ◽  
Author(s):  
Sivesh K Kamarajah ◽  
Sheraz R Markar ◽  
Pritam Singh ◽  
Ewen A Griffiths ◽  
Keyword(s):  
Online Survey ◽  
International Survey ◽  
Definitive Chemoradiotherapy ◽  
Available N ◽  
Cancer Management ◽  
Cancer Services ◽  
Esophagogastric Cancer ◽  
Polymerase Chain ◽  
Practice Variations ◽  
Tomography Scan

Abstract Background Several guidelines to guide clinical practice among esophagogastric surgeons during the COVID-19 pandemic were produced. However, none provide reflection of current service provision. This international survey aimed to clarify the changes observed in esophageal and gastric cancer management and surgery during the COVID-19 pandemic. Methods An online survey covering key areas for esophagogastric cancer services, including staging investigations and oncological and surgical therapy before and during (at two separate time-points—24th March 2020 and 18th April 2020) the COVID-19 pandemic were developed. Results A total of 234 respondents from 225 centers and 49 countries spanning six continents completed the first round of the online survey, of which 79% (n = 184) completed round 2. There was variation in the availability of staging investigations ranging from 26.5% for endoscopic ultrasound to 62.8% for spiral computed tomography scan. Definitive chemoradiotherapy was offered in 14.8% (adenocarcinoma) and 47.0% (squamous cell carcinoma) of respondents and significantly increased by almost three-fold and two-fold, respectively, in both round 1 and 2. There were uncertainty and heterogeneity surrounding prioritization of patients undergoing cancer resections. Of the surgeons symptomatic with COVID-19, only 40.2% (33/82) had routine access to COVID-19 polymerase chain reaction testing for staff. Of those who had testing available (n = 33), only 12.1% (4/33) had tested positive. Conclusions These data highlight management challenges and several practice variations in caring for patients with esophagogastric cancers. Therefore, there is a need for clear consistent guidelines to be in place in the event of a further pandemic to ensure a standardized level of oncological care for patients with esophagogastric cancers.

Implementing cognitive behavioral therapy for psychosis: An international survey of clinicians’ attitudes and obstacles.

2018 ◽  
Vol 41 (2) ◽  
pp. 141-148 ◽  
Author(s):  
Tania Lecomte ◽  
Crystal Samson ◽  
Farooq Naeem ◽  
Leslie Schachte ◽  
John Farhall
Keyword(s):  
Cognitive Behavioral Therapy ◽  
Behavioral Therapy ◽  
Cognitive Behavioral ◽  
International Survey

Peritoneal Dialysis Use and Practice Patterns: An International Survey Study

2020 ◽  
Author(s):  
Yeoungjee Cho ◽  
Aminu K. Bello ◽  
Adeera Levin ◽  
Meaghan Lunney ◽  
Mohamed A. Osman ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Practice Patterns ◽  
Survey Study ◽  
International Survey

Recent Strategies for Treating Stage IV Gastric Cancer: Roles of Palliative Gastrectomy, Chemotherapy, and Radiotherapy

2016 ◽  
Vol 25 (1) ◽  
pp. 87-94 ◽  
Author(s):  
Kunihiko Izuishi ◽  
Hirohito Mori
Keyword(s):  
Gastric Cancer ◽  
Performance Status ◽  
Locally Advanced ◽  
Growth Factor Receptor ◽  
Stage Iv ◽  
Stage Iv Gastric Cancer ◽  
Palliative Gastrectomy ◽  
Advanced Tumor ◽  
Esophagogastric Cancer ◽  
Previously Treated

Recently, many strategies have been reported for the effective treatment of gastric cancer. However, the strategy for treating stage IV gastric cancer remains controversial. Conducting a prospective phase III study in stage IV cancer patients is difficult because of heterogeneous performance status, age, and degree of cancer metastasis or extension. Due to poor prognosis, the variance in physical status, and severe symptoms, it is important to determine the optimal strategy for treating each individual stage IV patient. In the past decade, many reports have addressed topics related to stage IV gastric cancer: the 7th Union for International Cancer Control (UICC) TNM staging system has altered its stage IV classification; new chemotherapy regimens have been developed through the randomized ECF for advanced and locally advanced esophagogastric cancer (REAL)-II, S-1 plus cisplatin versus S-1 in RCT in the treatment for stomach cancer (SPIRITS), trastuzumab for gastric cancer (ToGA), ramucirumab monotherapy for previously-treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD), and ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously-treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW) trials; and the survival efficacy of palliative gastrectomy has been denied by the reductive gastrectomy for advanced tumor in three Asian countries (REGATTA) trial. Current strategies for treating stage IV patients can be roughly divided into the following five categories: palliative gastrectomy, chemotherapy, radiotherapy, gastric stent, or bypass. In this article, we review recent publications and guidelines along with above categories in the light of individual symptoms and prognosis. Abbreviations: APC: argon plasma coagulation; AVAGAST: anti-angiogenic antibody bevacizumab, the avastin in gastric cancer; BSC: best supportive care; CF: cisplatin and fluorouracil; CRP: C-reactive protein; DCF: docetaxel, cisplatin, and 5-FU; FISH: fluorescent in-situ hybridization; GJ: gastrojejunostomy; GPS: Glasgow Prognostic Score; HER: human epidermal growth factor receptor; HR: hazard ratio; NLR: neutrophil-to-lymphocyte ratio; OS: overall survival; PS: performance status; QOL: quality of life; RAINBOW: ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously-treated advanced gastric or gastro-oesophageal junction adenocarcinoma; RCTs: randomized controlled trials; REAL: randomized ECF for advanced and locally advanced esophagogastric cancer; REGARD: ramucirumab monotherapy for previously-treated advanced gastric or gastro-oesophageal junction adenocarcinoma; REGATTA: reductive gastrectomy for advanced tumor in three Asian countries; SEER: Surveillance Epidemiology and End Results; SEMS: self-expandable metal stents; SPIRITS: S-1 plus cisplatin versus S-1 in RCT in the treatment for stomach cancer; ToGA: trastuzumab for gastric cancer; TTP: time-to-progression; VEGFR: vascular endothelial growth factor receptor.

Descubrir, leer, publicar, compartir y monitorizar el progreso: comportamiento de los investigadores junior españoles

2020 ◽  
Author(s):  
Blanca Rodríguez-Bravo ◽  
David Nicholas
Keyword(s):  
Social Media ◽  
Scientific Communication ◽  
Open Science ◽  
Second Phase ◽  
International Survey ◽  
New Wave ◽  
Redes Sociales ◽  
Acceso Abierto ◽  
Use Of Social Media ◽  
Communication Habits

The scientific communication habits and practices of the new wave of Spanish researchers are analyzed based on the results of an international survey (2019). The results obtained from 100 participants support those previously obtained from interviews conducted between 2016 and 2018 in Spain under the Harbingers Project, and show similarities to and differences from those collected from the mentioned survey in other countries covered by the Project in its second phase. Spanish researchers have two contradictory faces: They are innovative in their perceptions but slightly less so in their practices regarding open access and the use of social media. However, these new attitudes and habits are motivated by a desire to promote their own work and gain recognition; In this sense, they are conservative. The competition in which they are immersed regarding the achievement of tenure and, therefore, the need to focus on their abilities that will be evaluated represent a limitation on enjoying the learning process and dedicating themselves to the practices of open science to which their generation is naturally prone. Resumen Se analizan los hábitos y prácticas de comunicación científica de la nueva ola de investigadores españoles a partir de los resultados de una encuesta de ámbito internacional (2019). Los resultados de un centenar de contribuciones confirman los obtenidos previamente en entrevistas realizadas entre 2016 y 2018 en España en el marco del Proyecto Harbingers, y ponen de manifiesto similitudes y diferencias con los resultados obtenidos de la encuesta mencionada en otros países cubiertos por el Proyecto en su segunda fase. Los investigadores españoles presentan dos caras contradictorias: Son innovadores en sus percepciones aunque no tanto en sus prácticas relativas al acceso abierto y al uso de las redes sociales. Sin embargo, sus actitudes y hábitos nuevos no son desinteresados, están motivados por promocionar el trabajo propio y conseguir el reconocimiento. En este sentido, se muestran conservadores. La competición en que se encuentran inmersos para conseguir un trabajo estable y, por tanto, la necesidad de focalizarse en los méritos que les van a ser evaluados les limita para poder disfrutar del proceso de aprendizaje y dedicarse a las prácticas de ciencia abierta a las que su generación se muestra proclive de forma natural.

Sign in / Sign up

Export Citation Format

Share Document